The pharmacogenomics of P-glycoprotein and its role in veterinary medicine

Journal of Veterinary Pharmacology and Therapeutics

Volumn 31, Issue 4, 2008, Pages 285-300

  Martinez, M ^a,b   Modric, S ^b   Sharkey, M ^b   Troutman, L ^b   Walker, L ^b   Mealey, K ^c  

^a Office of New Animal Drug Evaluation ^*  (United States)

^b Center for Veterinary Medicine   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEPROMAZINE; BUTORPHANOL; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DIGOXIN; DORAMECTIN; DOXORUBICIN; EPRINOMECTIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; INDINAVIR; ITRACONAZOLE; IVERMECTIN; KETOCONAZOLE; LACTONE DERIVATIVE; LOPERAMIDE; MACROCYCLIC COMPOUND; MILBEMYCIN; MOXIDECTIN; PACLITAXEL; QUERCETIN; QUINIDINE; SELAMECTIN; TALINOLOL; TRICLABENDAZOLE; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ARTICLE; DISEASE PREDISPOSITION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG RESPONSE; ENTERITIS; ENVIRONMENTAL STRESS; GENETIC VARIABILITY; HUMAN; NEUROTOXICITY; NONHUMAN; PHARMACOGENOMICS; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SPECIES DIFFERENCE; VETERINARY MEDICINE;

ANIMALS; BLOOD-BRAIN BARRIER; HUMANS; P-GLYCOPROTEIN; PHARMACOGENETICS; PHENOTYPE; SPECIES SPECIFICITY; VETERINARY MEDICINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 47349109041     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2008.00964.x     Document Type: Article

References (178)

1. Advantage Multi, Nada 141-251. Freedom of Information Summary. Available at: http://www.fda.gov/cvm/FOI/141-251o122006.pdf (accessed 29 August 2007).
2. Achira, M., Totsuka, R., Fujimura, H. Kume, T. (2002) Tissue-specific regulation of expression and activity of P-glycoprotein in adjuvant arthritis rats. European Journal of Pharmaceutical Sciences, 16, 29 36.
3. Allenspach, K., Rüfenacht, S., Sauter, S., Gröne, A., Steffan, J., Strehlau, G. Gaschen, F. (2006a) Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid-refractory inflammatory bowel disease. Journal of Veterinary Internal Medicine, 20, 239 244.
4. Allenspach, K., Bergman, P.J., Sauter, S., Grone, A., Doherr, M.G. Gaschen, F. (2006b) P-gp expression in lamina propria lymphocytes of duodenal biopsy samples in dogs with chronic idiopathic enteropathies. Journal of Comparative Pathology, 134, 1 7.
5. Alvarez, A.I., Merino, G., Molina, A.J., Pulido, M.M., McKellar, Q.A. Prieto, J.G. (2006) Role of ABC transporters in veterinary drug research and parasite resistance. Current Drug Delivery, 3, 199 206.
6. Ambudkar, S.V., Kim, I.W. Sauna, Z.E. (2006) The power of the pump: mechanisms of P-gp (ABCB1). European Journal of Pharmaceutical Sciences, 27, 392 400.
7. Annese, V., Valvano, M.R., Palmieri, O., Latiano, A., Bossa, F. Andriulli, A. (2006) Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World Journal of Gastroenterology, 12, 3636 3644.
8. Atkinson, D.E., Brice-Bennett, S. D'Souza, S.W. (2007) Antiepileptic medication during pregnancy: does fetal genotype affect outcome? Pediatric Research, 62, 120 127.
9. Awara, W.M., El-Sisi, A.E., El-Sayad, M.E. Goda, A.E. (2004) The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? Pharmacological Research, 50, 487 498.
10. Ayrton, A. Morgan, P. (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica, 31, 469 497.
11. Baker, E.K., Johnstone, R.W., J Zalcberg, R.W. El-Osta, A. (2005) Epigenetic changes to the MDR-1 locus in response to chemotherapeutic drugs. Oncogene, 24, 8061 8075.
12. Baltes, S., Gastens, A.M., Fedrowitz, M., Potschka, H., Kaever, V. Loscher, W. (2007) Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology, 52, 333 346.
13. Barnes, D.M. (2001) Expression of P-gp in the chicken. Comparative biochemistry and physiology part a: molecular & integrative physiology, 130, 301 310.
14. Bendayan, R., Ronaldson, P.T., Gingras, D. Bendayan, M. (2006) In situ localization of P-glycoprotein (ABCB1) in human and rat brain. Journal of Histochemistry and Cytochemistry, 54, 1159 1167.
15. Beugnet, F., Gauthey, M. Kerboeuf, D. (1997) Partial in vitro reversal of benzimidazole resistance by the free-living stages of Haemonchus contortus with verapamil. Veterinary Record, 141, 575 576.
16. Brady, J.M., Cherrington, N.J., Hartley, D.P., Buist, S.C., Li, N. Klassen, C.D. (2002) Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metabolism Disposition, 30, 838 844.
17. Breier, A., Barančik, M., Sulováa, Z. Uhrik, B. (2005) P-gp - implications of metabolism of neoplastic cells and cancer therapy. Current Cancer Drug Targets, 5, 457 468.
18. Campbell, Neil 1996) "Methods: Sequencing of DNA by the Sanger Method." Biology. 4th edn, p. 324. Benjamin/Cummings Publishing Co., New York.
19. Chang, T., Benet, L.Z. Hebert, M.F. (1996) The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clinical Pharmacology and Therapeutics, 59, 297 303.
20. Chaudhary, P.M. Roninson, I.B. (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. Journal of the National Cancer Institute, 85, 632 639.
21. Chen, C., Clark, D., Ueda, K., Pastan, I., Gottesman, M.M. Roninson, I.B. (1990) Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. Journal of Biological Chemistry, 265, 506 514.
22. Chen, C., Liu, X. Smith, B.J. (2003) Utility of mdr1-gene deficient mice in assessing the impact of P-glycoprotein on the pharmacokinetics and pharmacodynamics in drug discovery and development. Current Drug Metabolism, 4, 272 291.
23. Collnot, E.M., Baldes, C., Wempe, M.F., Hyatt, J., Navarro, L., Edgar, K.J., Schaefer, U.F. Lehr, C.M. (2006) Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. Journal of Controlled Release, 111, 35 40.
24. Collnot, E.M., Baldes, C., Wempe, M.F., Kappl, R., Hüttermann, J., Hyatt, J.A., Edgar, K.J., Schaefer, U.F. Lehr, C.M. (2007) Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Molecular Pharmaceutics, 4, 465 474.
25. Cordon-Cardo, C., O'Brien, J.P., Casals, D., Rittman-Grauer, L., Biedler, J.J., Melamed, M.R. Bertino, J.R. (1989) Multi-drug-resistance gene (P-gp) is expressed by endothelial cells at blood-brain-barrier sites. Proceedings of the National Academy of Sciences of the United States of America, 86, 695 698.
26. van der Deen, M., de Vries, E.G.E., Timens, W., Scheper, R.J., Timmer-Bosscha, H. Postma, D.S. (2005) ATP-binding cassette (ABC) transporters in normal and pathological lung. Respiratory Research, 6, 59 74.
27. Dhir, R., Buschman, E. Gros, P. (1990) Structural and functional characterization of the mouse multidrug resistance gene family. Bulletin du Cancer, 77, 1125 1129.
28. Didziapetris, R., Japertas, P., Avdeef, A. Petrauskas, A. (2003) Classification analysis of P-gp substrate specificity. Journal of Drug Targeting, 11, 391 406.
29. Dohgu, S., Yamauchi, A., Nakagawa, S., Takata, F., Kai, M., Egawa, T., Naito, M., Tsuruo, T., Sawada, Y., Niwa, M. Kataoka, Y. (2004) Nitric oxide mediates cyclosporine-induced impairment of the blood-brain barrier I cocultures of mouse brain endothelia cells and rat astrocytes. European Journal of Pharmacology, 505, 51 59.
30. Dupuy, J., Larrieu, G., Sutra, J.F., Lespine, A. Alvinerie, M. (2003) Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Veterinary Parasitology, 112, 337 347.
31. Eichelbaum, M., Fromm, M.F. Schwab, M. (2004) Clinical aspects of the MDR-1 (ABCB1) gene polymorphism. Therapeutic Drug Monitoring, 26, 180 185.
32. Endres, C.J., Hsiao, P., Chung, F.S. Unadkat, J.D. (2006) The role of transporters in drug interactions. European Journal of Pharmaceutical Sciences, 27, 501 517.
33. Eriksson, U.G., Dorani, H., Karlsson, J., Fritsch, H., Hoffmann, K.J., Olsson, L., Sarich, T.C., Wall, U. Schutzer, K.M. (2006) Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-gp-mediated excretion. Drug Metabolism and Disposition, 34, 775 782.
34. Ernest, S. Bello-Reuss, E. (1998) P-gp functions and substrates: possible roles of MDR-1 gene in the kidney. Kidney International, 65, S11 S17.
35. Ernest, S., Rajaraman, S., Megyei, J. Bello-Reuss, S.N. (1997) Expression of MDR-1 (multi-drug resistance) gene and its protein in normal human kidney. Nephron, 77, 284 289.
36. Farrell, R.J. Kelleher, D. (2003) Glucocorticoid resistance in inflammatory bowel disease. Journal of Endocrinology, 178, 339 346.
37. Farrell, R.J., Murphy, A., Long, A., Donnelly, S., Cherikuri, A., O'Toole, D., Mahmud, N., Keeling, P.W., Weir, D.G. Kelleher, D. (2000) High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology, 118, 279 288.
38. FDA (2005) Guidance for Industry: Pharmacogenomic Data Submission. Available at: http://www.fda.gov/cder/guidance/6400fn1.pdf (accessed 4 March 2008).
39. Fernandez, C., Buyse, M., German-Fattal, M. Gimenez, F. (2004) Influence of the pro-inflammatory cytokines on P-gp expression and functionality. Journal of Pharmacy and Pharmaceutical Sciences, 17, 359 371.
40. Fleischer, S., Sharkey, M., Mealey, K., Ostrander, E. Martinez, M. (2008) Pharmacogenetic and metabolic differences between dog breeds: their impact on canine medicine and the use of the dog as a preclinical animal model, in press.
41. Frueh, F.W. Gurwitz, D. (2004) From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics, 5, 571 579.
42. Fujita, T., Washio, K., Takabatake, D., Takahashi, H., Yoshitomi, S., Tsukuda, K., Ishibe, Y., Ogasawara, Y., Doihara, H. Shimizu, N. (2005) Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. International Journal of Cancer, 20, 670 682.
43. Geick, A., Eichelbaum, M. Burk, O. (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampicin. Journal of Biological Chemistry, 276, 14581 14587.
44. Geyer, J., Döring, B., Godoy, J.R., Leidolf, R., Moritz, A. Petzinger, E. (2005) Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany. Journal of Veterinary Pharmacology and Therapeutics, 28, 545 551.
45. Griffin, J., Fletcher, N., Clemence, R., Blanchflower, S. Brayden, D.J. (2005) Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. Journal of Veterinary Pharmacology and Therapeutics, 28, 257 265.
46. Gros, P. Buschman, E. (1993) The mouse multi-drug resistance gene family: structural and functional analysis. International Review of Cytology, 137C, 169 197.
47. Hennessy, M. Spiers, J.P. (2007) A primer on the mechanics of P-gp the multidrug transporter. Pharmacological Research, 55, 1 15.
48. Hennessy, D.R., Page, S.W. Gottschall, D. (2000) The behaviour of doramectin in the gastrointestinal tract, its secretion in bile and pharmacokinetic disposition in the peripheral circulation after oral and intravenous administration to sheep. Journal of Veterinary Pharmacology and Therapeutics, 23, 203 213.
49. Ho, E.A. Piquette-Miller, M. (2006) Regulation of multidrug resistance by pro-inflammatory cytokines. Current Cancer Drug Targets, 6, 295 311.
50. Hu, Z., Jin, S. Scotto, K.W. (2000) Transcriptional activation of the MDR1 gene by UV irradiation. Journal of Biological Chemistry, 275, 2979 2985.
51. Huff, L.M., Wang, Z., Iglesias, A., Fojo, T. Lee, J.S. (2005) Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples. Cancer Research, 65, 11694 11703.
52. Hugnet, C., Bentjen, S.A. Mealey, K.L. (2004) Frequency of the mutant MDR-1 allele associated with multi-drug sensitivity in a sample of collies from France. Journal of Veterinary Pharmacology and Therapeutics, 27, 227 229.
53. Idriss, H.T., Hannun, Y.A., Boulpaep, E. Basavappa, S. (2000) Regulation of volume-activated chloride channels by P-gp: phosphorylation has the final say! Journal of Physiology, 524, 629 636.
54. Jansen, G., Scheper, R.J. Dijkmans, B.A. (2003) Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview. Scandinavian Journal of Rheumatology, 32, 325 336.
55. Joy, M.S., Nickeleit, V., Hogan, S.L., Thompson, B.D. Finn, W.F. (2005) Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy, 25, 779 789.
56. Juliano, R.L. Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta, 11, 152 162.
57. Kageyama, M., Namiki, H., Fukushima, H., Ito, Y., Shibata, N. Takada, K. (2005) In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biological and Pharmaceutical Bulletin, 28, 316 322.
58. Kalvass, J.C., Maurer, T.S. Pollack, G.M. (2007) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metabolism and. Disposition, 35, 660 666.
59. Karyekar, C.S., Eddington, N.D., Briglia, A., Gubbins, P.O. Dowling, T.C. (2004) Renal interaction between itraconazole and cimetidine. Journal of Clinical Pharmacology, 44, 919 927.
60. Katoh, M., Suzuyama, N., Takeuchi, T., Yoshitomi, S., Asahi, S. Yokoi, T. (2006) Kinetic analyses for species differences in P-gp-mediated drug transport. Journal of Pharmaceutical Sciences, 95, 2673 2683.
61. Kawaguchi, H., Matsui, Y., Watanaabe, Y. Takakura, Y. (2004) Effect of interferon-gamma on the pharmacokinetics of digoxin, a P-glycoprotein substrate, intravenously injected into the mouse. Journal of Pharmacology and Experimental Therapeutics, 308, 91 96.
62. Kerboeuf, D., Guegnard, F. Le Vern, Y. (2002) Analysis and partial reversal of multidrug resistance to anthelmintics due to P-glycoprotein in Haemonchus contortus eggs using Lens culinaris lectin. Parasitology Research, 88, 816 821.
63. Kerboeuf, D., Blackhalla, W., Kaminskyc, R. von Samson-Himmelstjerna, G. (2003) P-gp in helminths: function and perspectives for anthelmintic treatment and reversal of resistance. International Journal of Antimicrobial Agents, 22, 332 346.
64. Kim, S.K., Lim, S.Y., Wang, K.C., Kim, Y.Y., Chi, J.G., Choi, Y.L., Shin, H.J. Cho, B.K. (2004) Over-expression of cyclooxygenase-2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi-drug resistance in vitro. Oncology Reports, 12, 403 409.
65. Klimecki, W.T., Futscher, B.W., Grogan, T.M. Dalton, W.S. (1994) P-gp expression and function in circulating blood cells from normal volunteers. Blood, 83, 2451 2458.
66. Kortekaas, R., Leenders, K.L., van Oostrom, J.C., Vaalburg, W., Bart, J., Willemsen, A.T. Hendrikse, N.H. (2005) Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Annals of Neurology, 57, 176 179.
67. Kramer, R., Weber, T.K., Arceci, R., Ramchurren, N., Kastrinakis, W.V., Steele, G. Jr. Summerhayes, I.C. (1995) Inhibition of N-linked glycosylation of P-gp by tunicamycin results in a reduced multi-drug resistance phenotype. British Journal of Cancer, 71, 670 675.
68. Kwon, Y., Kamath, A.V. Morris, M. (1996) Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles. Journal of Pharmaceutical Sciences, 85, 935 939.
69. Lage, H. (2003) ABC-transporters:implications on drug resistance from microorganisms to human cancers. International Journal of Antimicrobial Agents, 22, 188 199.
70. Lankas, G.R., Wise, L.D., Carwright, M.E., Pippert, T. Umbenhauer, D.R. (1998) Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reproductive Toxicology, 12, 457 463.
71. Launay-Vacher, V., Izzedine, H., Karie, S., Hulot, J.S., Baumelou, A. Deray, G. (2006) Renal tubular drug transporters. Nephron Physiology, 103, 97 106.
72. Lecureur, V., Courtois, A., Payen, L., Verhnet, L., Guillouzo, A. Fardel, O. (2000) Expression and regulation of hepatic drug and bile acid transporters. Toxicology, 153, 203 219.
73. Ledoux, S., Yang, R., Friedlander, G. Laouari, D. (2003) Glucose depletion enhances P-gp expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Research, 63, 284 290.
74. Lee, I.K., Lee, Y.M., Song, I.S., Chung, S.J., Kim, S.G., Lee, M.G. Shim, C.K. (2002) Hepatobiliary excretion of tributylmethylamonium in rats with lipopolysaccharide-induced acute inflammation. Archives of Pharmaceutical Research, 25, 969 972.
75. Lee, Y.J., Chung, S.J. Shim, C.K. (2005) Limited role of P-glycoprotein in the intestinal absorption of cyclosporin A. Biological and Pharmaceutical Bulletin, 28, 760 763.
76. Lee, J.Y., Tanabe, S., Shimohira, H., Kobayashi, Y., Oomachi, T., Azuma, S., Ogihara, K. Inokuma, H. (2007) Expression of cyclooxygenase-2, P-gp and multi-drug resistance-associated protein in canine transitional cell carcinoma. Research in Veterinary Science, 83, 210 216.
77. Lemaire, S., Van Bambeke, F., Mingeot-Leclercq, M.P. Tulkens, P.M. (2007) Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells. Antimicrobial Agents Chemotherapy, 51, 2748 2757.
78. Lesko, L.J. Woodcock, J. (2004) Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nature Reviews. Drug Discovery, 3, 763 769.
79. Lespine, A., Martin, S., Dupuy, J., Roulet, A., Pineau, T., Orlowski, S. Alvinerie, M. (2007) Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. European Journal of Pharmaceutical Sciences, 30, 84 94.
80. Levy, S.B. (1992) Active efflux mechanisms for antimicrobial resistance. Antimicrobial Agents and Chemotherapy, 36, 695 703.
81. Li, X.Z. Nikaido, H. (2004) Efflux-mediated drug resistance in bacteria. Drugs, 64, 159 204.
82. Lomovskaya, O. Watkins, W.J. (2001) Efflux pumps: their role in antibacterial drug discovery. Current Medicinal Chemistry, 8, 1699 1711.
83. Lomovskaya, O., Warren, M.S., Lee, A., Galazzo, J., Fronko, R., Lee, M., Blais, J., Cho, D., Chamberland, S. Renau, T. (2001) Identification and characterization of inhibitors of multi-drug resistance efflux pumps in P. aeruginosa: novel agents for combination. Antimicrobial Agents and Chemotherapy, 45, 105 116.
84. Lomovskaya, O., Zgurskaya, H.I., Totrov, M. Watkins, W.J. (2007) Waltzing transporters and 'the dance macabre' between humans and bacteria. Nature Reviews Drug Discovery, 6, 56 65.
85. Longley, M., Phua, S.H., van Stijn, T.C. Crawford, A.M. (1999) Isolation and mapping of the first ruminant multidrug resistance genes. Animal Genetics, 30, 207 210.
86. Loo, T.W. Clarke, D.M. (2005) Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. Journal of Membrane Biology, 206, 173 185.
87. MacFarland, A., Abramovich, D.R., Ewen, S.W. Pearson, C.K. (1994) Stage-specific distribution of P-gp in first-trimester and full-term human placenta. Histochemical Journal, 26, 417 423.
88. Majumdar, S., Duvvuri, S. Mitra, A.K. (2004) Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. Advanced Drug Delivery Reviews, 56, 1437 1452.
89. Manach, C., Scalbert, A., Morand, C., Remesy, C. Jimenez, L. (2004) Polyphenols: food sources and bioavailability. American Journal of Clinical Nutrition, 79, 727 747.
90. Marchetti, S., Mazzanti, R., Beijnen, J.H. Schellens, J.H. (2007) Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist, 12, 927 941.
91. Marino, P.A., Gottesman, M.M. Pastan, I. (1990) Regulation of the multidrug resistance gene in regenerating rat liver. Cell Growth & Differentiation, 1, 57 62.
92. Martin, C., Berridge, G., Higgins, C.F., Mistry, P., Charleton, P. Callaghan, R. (2000) Communication between multiple drug binding sites on P-gp. Molecular Pharmacology, 58, 624 632.
93. Martinez, M.N. Amidon, G.L. (2002) A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. Journal of Clinical Pharmacology, 42, 620 643.
94. McEntee, M., Silverman, J.A., Rassnick, K., Zgola, M., Chan, A.O., Tau, P.T. Page, R.L. (2003) Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Veterinary and Comparative Oncology, 2, 105 112.
95. McKeegan, K.S., Borges-Walmsley, M.I. Walmsley, A.R. (2004) Structural understanding of efflux-mediated drug resistance: potential routes to efflux inhibition. Current Opinion in Pharmacology, 4, 479 486.
96. Mealey, K.L. (2004) Therapeutic implications of the MDR-1 gene. Journal of Veterinary Pharmacology and Therapeutics, 27, 257 264.
97. Mealey, K.L. (2006) Adverse drug reactions in herding-breed dogs: The role of P-gp. Compendium, January 2006, 28, 23 33.
98. Mealey, K.L. Bentjen, S.A. (2003) Sequence and structural analysis of the presumed downstream promoter of the canine mdr1 gene. Veterinary and Comparative Oncology, 1, 30 35.
99. Mealey, K.L., Barhoumi, R., Rogers, K. Kochevar, D.T. (1998) Doxorubicin induced expression of P-gp in a canine osteosarcoma cell line. Cancer Letters, 126, 187 192.
100. Mealey, K.L., Bentjen, S.A., Gay, J.M. Cantor, G.H. (2001) Ivermectin sensitivity in Collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics, 11, 727 733.
101. Mealey, K.L., Bentjen, S.A. Waiting, D.K. (2002a) Frequency of the mutant MDR-1 allele associated with ivermectin sensitivity in a sample population of collies from the northwestern United States. American Journal of Veterinary Research, 63, 479 481.
102. Mealey, K.L., Barhoumi, R., Burghardt, B., Safe, S. Kochevar, D.T. (2002b) Doxycycline induces expression of P-glycoprotein as effectively as doxorubicin in MCF-7 breast carcinoma cells. Antimicrobial Agents and Chemotherapy, 46, 755 761.
103. Mealey, K.L., Bentjen, S.A., Gay, J.M. Hosick, H.L. (2003a) Dexamethasone treatment of a canine, but not human, tumor cell line increases chemoresistance independent of P-glycoprotein and multidrug resistance-related protein expression. Veterinary and Comparative Oncology, 1, 67 75.
104. Mealey, K.L., Northrop, N.C. Bentjen, S.A. (2003b) Increased susceptibility to P-glycoprotein substrate chemotherapeutic agents in a Collie with the MDR1 deletion mutation associated with ivermectin sensitivity. Journal of the American Veterinary Medical Association, 223, 1453 1455.
105. Mealey, K.L., Gay, J.M., Martin, L.G. Waiting, D.K. (2007) Comparison of the hypothalamic-pituitary-adrenal axis in MDR1-1Δ and MDR1 wildtype dogs. Journal of Veterinary Emergency and Critical Care, 17, 61 66.
106. Miller, D.S. (2002) Xenobiotic export pumps, endothelin signaling, and tubular nephrotoxicants - a case of molecular hijacking. Journal of Biochemical and Molecular Toxicology, 16, 121 127.
107. Mizutani, T. Hattori, A. (2005) New horizon of MDR1 (P-glycoprotein) study. Drug Metabolism Reviews, 37, 489 510.
108. Molento, M.B. Prichard, R.K. (1999) Effects of the multi-drug-resistance- reversing agents verapamil and CL 347,099 on the efficacy of ivermectin or moxidectin against unselected and drug-selected strains of Haemonchus contortus in jirds (Meriones unguiculatus). Parasitology Research, 85, 1007 1011.
109. Molento, M.B., Lifschitz, A., Sallovitz, J., Lanusse, C. Prichard, R. (2004) Influence of verapamil on the pharmacokinetics of the antiparasitic drugs ivermectin and moxidectin in sheep. Parasitology Research, 92, 121 127.
110. del Moral, R.G., Olmo, A., Aguilar, M. O'Valle, F. (1998) P glycoprotein: a new mechanism to control drug-induced nephrotoxicity. Experimental Nephrology, 6, 89 97.
111. Mottier, L., Alvarez, L., Fairweather, I. Lanusse, C. (2006) Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect. Journal of Parasitology, 92, 1355 1360.
112. Muller, M. Jansen, P.L.M. (1997) Molecular aspects of hepatobiliary transport. American Journal of Physiology, 272, G1285 G1303.
113. National Center for Biotechnology Information. One Size Does Not Fit All: the Promise of Pharmacogenomics. Available at: http://www.ncbi.nlm.nih.gov/ About/primer/pharm.html (accessed 1 July 2007).
114. Neff, M.W., Robertson, K.R., Wong, A.K., Safra, N., Broman, K.W., Slatkin, M., Mealey, K.L. Pedersen, N.C. (2004) Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proceedings of the National Academy of Sciences of the United States of America, 101, 11725 11730.
115. Nikaido, H. Zgurskaya, H.I. (1999) Antibiotic efflux mechanisms. Current Opinion in Infectious Diseases, 12, 529 536.
116. Nobili, S., Landini, I., Giglioni, B. Mini, E. (2006) Pharmacological strategies for overcoming multi-drug resistance. Current Drug Targets, 7, 861 879.
117. O'Connor, R. (2007) The pharmacology of cancer resistance. Anticancer Research, 27, 1267 1272.
118. Ogihara, T., Kamiya, M., Ozawa, M., Fujita, T., Yamamoto, A., Yamashita, S., Ohnishi, S. Isomura, Y. (2006) What kinds of substrates show P-gp-dependent intestinal absorption? Comparison of verapamil and vinblastine Drug Metabolism and Pharmacokinetics, 21, 238 244.
119. Ohtsuki, S. Terasaki, T. (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharmaceutical Research, 24, 1745 1758.
120. Okamura, N., Hirai, M., Tanigawara, Y., Tanaka, K., Yasuhara, M., Ueda, K., Komano, T. Hori, R. (1993) Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. Journal of Pharmacology and Experimental Therapeutics, 266, 1614 1619.
121. Page, R.L., Hughes, C.S., Huyan, S., Sagris, J. Trogdon, M. (2000) Modulation of P-gp-mediated doxorubicin resistance in canine cell lines. Anticancer Research, 20, 3533 3538.
122. Pang, D.C., Amidon, G.L., Preusch, P.C. Sadee, W. (1999) Meeting Report. Second AAPS-NIH frontier symposium 1999: membrane transporters and drug therapy. AAPS PharmSci, 1, E7.
123. Patel, V.A., Dunn, M.J. Sorokin, A. (2002) Regulation of MDR-1 (P-gp) by cyclooxygenase-2. Journal of Biological Chemistry, 277, 38915 38920.
124. Patricelli, A.J., Hardie, R.J. McAnulty, J.E. (2002) Cyclosporin and ketoconazole for the treatment of perianal fistulas in dogs. Journal of the American Veterinary Medical Association, 220, 1009 1016.
125. Peréz-Tomás, R. (2006) Multi-drug resistance: retrospect and prospects in anti-cancer drug treatment. Current Medicinal Chemistry, 13, 1859 1876.
126. Perrière, N., Yousif, S., Cazaubon, S., Chaverot, N., Bourasset, F., Cisternino, S., Declèves, X., Hori, S., Terasaki, T., Deli, M., Scherrmann, J.M., Temsamani, J., Roux, F. Couraud, P.O. (2007) A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Brain Research, 1150, 1 13.
127. Piddock, L.J. (2006) Clinically relevant chromosomally encoded multi-drug resistance efflux pumps in bacteria. Clinical Microbiology Reviews, 19, 382 402.
128. Piquette-Miller, M., Pak, A., Kim, H., Anari, R. Shahzamani, A. (1998) Decreased expression and activity of P-gp in rat liver during acute inflammation. Pharmaceutical Research, 15, 706 711.
129. Polli, J.W., Wring, S.A., Humphreys, J.E., Huang, L., Morgan, J.B., Webster, L.O. Serabjit-Singh, C.S. (2001) Rational use of in vitro P-gp assays in drug discovery. Journal of Pharmacology and Experimental Therapeutics, 299, 620 628.
130. Pomroy, W.E. (2006) Anthelmintic resistance in New Zealand: a perspective on recent findings and options for the future. New Zealand Veterinary Journal, 54, 265 270.
131. Ponte-Sucre, A. (2007) Availability and application of ATP-binding cassette (ABC) transporter blockers. Applied Microbiology and Biotechnology, 76, 279 286.
132. Prichard, R.K. Roulet, A. (2007) ABC transporters and beta-tubulin in macrocyclic lactone resistance: prospects for marker development. Parasitology, 134, 1123 1132.
133. Rao, V.V., Dahleimer, J.L., Bardgett, M.E., Snyder, A.Z., Finch, R.A., Sartorelli, A.C. Piwnica-Worms, D. (1999) Choroid plexus epithelia expression of MDR1 P glycoprotein and multi-drug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proceedings of the National Academy of Sciences of the United States of America, 96, 3900 3905.
134. Raymond, M., Rose, E., Houseman, D.E. Gros, P. (1990) Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistant cells. Molecular and Cellular Biology, 10, 1642.
135. Rege, B.D., Kao, J.P. Polli, J.E. (2002) Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. European Journal of Pharmaceutical Sciences, 16, 237 246.
136. Roberts, M.S., Magnusson, B.M., Burczynski, F.J. Weiss, M. (2002) Enterohepatic circulation: physiological, pharmacokinetic, and clinical implications. Clinical Pharmacokinetics, 41, 751 790.
137. Romiti, N., Tramonti, G., Donati, A. Chieli, E. (2004) Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sciences, 76, 293 302.
138. Ronald, P.J., Elferink, O. Paulusma, C.C. (2007) Function and pathophysiological importance of ABCB4 (MDR3 P-gp). Pflugers Arch - European Journal Physiology, 453, 601 610.
139. Roulet, A., Puel, O., Gesta, S., Lepage, J.F., Drag, M., Soll, M., Alvinerie, M. Pineau, T. (2003) MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. European Journal of Pharmacology, 460, 85 91.
140. Sangster, N. Dobson, R.J. (2002) Anthelmintic resistance. In The Biology of Nematodes. Ed. Lee, D.L., pp. 531 567. CRC Press, London.
141. Sangster, N.C., Bannan, S.C., Weiss, A.S., Nulf, S.C., Klein, R.D. Geary, T.G. (1999) Haemonchus contortus: sequence heterogeneity of internucleotide binding domains from P-gps and an association with avermectin/milbemycin resistance. Experimental Parasitology, 91, 250 257.
142. Sartor, L.L., Bentjen, S., Trepanier, L. Mealey, K. (2004) Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. Journal of Veterinary Internal Medicine, 18, 117 118.
143. Scala, S., Akhmed, N., Rao, U.S., Paull, K., Lan, L.B., Dickstein, B., Lee, J.S., Elgemeie, G.H., Stein, W.D. Bates, S.E. (1997) P-gp substrates and antagonists cluster into two distinct groups. Molecular Pharmacology, 51, 1024 1033.
144. Schinkel, A.H., Kemp, S., Dolle, M., Rudenko, G. Wagenaar, E. (1993) N-glycosylation and deletion mutants of the human MDR1 P-gp. Journal of Biological Chemistry, 268, 7474 7481.
145. Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P., Berns, A.J.M. Borst, P. (1994) Disruption of the mouse mdr1a P-gp gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77, 491 502.
146. Schinkel, A.H., Mol, C.A., Wagenaar, E., van Deemter, L., Smit, J.J. Borst, P. (1995a) Multi-drug resistance and the role of P-gp knockout mice. European Journal of Cancer, 31A, 1295 1298.
147. Schinkel, A.H., Wagenaar, E., van Deemter, L., Mol, C.A. Borst, P. (1995b) Absence of mdr1a P-gp in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporine A. Journal of Clinical Investigation, 96, 1698 1705.
148. Schinkel, A.H., Mayer, U., Wagenaar, E., Mol, C.A., van Deemter, L., Smit, J.J., van der Valk, M.A., Voordouw, A.C., Spits, H., van Tellingen, O., Zijlmans, J.M., Fibbe, W.E. Borst, P. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-gps. Proceedings of the National Academy of Sciences of the United States of America, 94, 4028 4033.
149. Schmidt, D. Losscher, W. (2005) Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia, 46, 858 877.
150. Sharom, F.J. (2006) Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochemistry and Cell Biology, 84, 979 992.
151. Shitara, Y., Horie, T. Sugiyama, Y. (2006) Transporters as a determinant of drug clearance and tissue distribution. European Journal of Pharmaceutical Sciences, 27, 425 446.
152. Smit, J.J., Schinkel, A.H., Mol, C.A., Majoor, D., Mooi, W.J., Jonqsma, A.P., Lincke, C.R. Borst, P. (1994) Tissue distribution of the human MDR3 P-glycoprotein. Laboratory Investigation, 75, 638 649.
153. Sorokin, A. (2004) Cyclooxygenase-2: potential role in regulation of drug efflux and multi-drug resistance phenotype. Current Pharmaceutical Design, 10, 647 657.
154. Sparreboom, A., Van Asperen, J., Mayer, U., Schinkel, A.H., Smit, J.W., Meijer, D.K., Borst, P., Nooijen, W.J., Beijnen, J.H. van Tellingen, O. (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-gp in the intestine. Proceedings of the National Academy of Sciences of the United States of America, 94, 2031 2035.
155. Sugawara, I., Kataoka, I., Morishita, Y., Hamada, H., Tsuruo, T., Itoyama, S. Mori, S. (1988) Tissue distribution of P-glycoprotein encoded by a multidrug resistant gene as revealed by a monoclonal antibody, MRK16. Cancer Research, 48, 1926 1929.
156. Sun, J., He, Z.-G., Cheng, G., Wang, S.-J., Hao, H.-X. Zou, M.-J. (2004) Multi-drug resistance P-gp: crucial significance in drug disposition and interaction. Medical Science Monitor, 10, RA5 RA14.
157. Sun, H., Frassetto, L. Benet, L.Z. (2006) Effects of renal failure on drug transport and metabolism. Pharmacology & Therapeutics, 109, 1 11.
158. Susanto, M. Benet, L.Z. (2002) Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharmaceutical Research, 19, 457 462.
159. Suzuyama, N., Katoh, M., Takeuchi, T., Yoshitomi, S., Higuchi, T., Asashi, S. Yokoi, T. (2007) Species differences of inhibitory effects on P-gp-mediated drug transport. Journal of Pharmaceutical Sciences, 96, 1609 1618.
160. Takeuchi, T., Yoshitomi, S., Higuchi, T., Ikemoto, K., Niwa, S., Ebihara, T., Katoh, M., Yokoi, T. Asahi, S. (2006) Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharmaceutical Research, 23, 1460 1472.
161. Tanigawara, Y., Okamura, N., Hirai, M., Yasuhara, M., Ueda, K., Kioka, N., Komano, T. Hori, R. (1992) Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). Journal of Pharmacology and Experimental Therapeutics, 263, 840 845.
162. Terlouw, S.A., Masereeuw, R., Russel, F.G. Miller, D.S. (2001) Nephrotoxicants induce endothelin release and signaling in renal proximal tubules: effect on drug efflux. Molecular Pharmacology, 59, 1433 1440.
163. Theibaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I. Willingham, M.C. (1987) Cellular localization of the multi-drug-resistance gene product P-gp in normal human tissues. Proceedings of the National Academy of Sciences of the United States of America, 84, 7735 7738.
164. Tranquilli, W.J., Paul, A.J. Todd, K.S. (1991) Assessment of toxicosis induced by high-dose administration of milbemycin oxime in Collies. American Journal of Veterinary Research, 52, 1170 1172.
165. Tsatsanis, C., Androulidaki, A., Venihaki, M. Margioris, A.N. (2006) Signaling networks regulating cyclooxygenase-2. International Journal of Biochemistry and Cell Biology, 38, 1654 1661.
166. Tsuro, T. (2003) Molecular cancer therapeutics: recent progress and targets in drug resistance. Internal Medicine, 42, 237 243.
167. Ueda, K., Cardarelli, C., Gottesman, M.M. Pastan, I. (1987) Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proceedings of the National Academy of Sciences of the United States of America, 84, 3004 3008.
168. Umbenhauer, D.R., Lankas, G.R., Pippert, T.R., Wise, L.D., Cartwright, M.E., Hall, S.J. Beare, C.M. (1997) Identification of a P-gp-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicology and Applied Pharmacology, 146, 88 94.
169. Wagner, D., Spahn-Langguth, H., Hanafy, A., Koggel, A. Langguth, P. (2001) Intestinal drug efflux: formulation and food effects. Advanced Drug Delivery Reviews, 50, S13 S31.
170. Wang, Y.H., Chao, P.D.L., Hsiu, S.L., Wen, K.C. Hou, Y.C. (2004) Lethal quercetin-digoxin interaction in pigs. Life Sciences, 74, 1191 1197.
171. Xia, C.Q., Xiao, G., Liu, N., Pimprale, S., Fox, L., Patten, C.J., Crespi, C.L., Miwa, G. Gan, L.S. (2006) Comparison of species differences of P-gps in beagle dog, rhesus monkey, and human using Atpase activity assays. Molecular Pharmacology, 3, 78 86.
172. Xia, C.Q., Milton, M.N. Gan, L.S. (2007) Evaluation of drug-transporter interactions using in vitro and in vivo models. Current Drug Metabolism, 8, 341 363.
173. Xu, M., Molento, M., Blackhall, W., Ribeiro, P., Beech, R. Prichard, R. (1998) Ivermectin resistance in nematodes may be caused by alteration of P-gp homolog. Molecular and Biochemical Parasitology, 91, 327 335.
174. Yague, E., Armesilla, A.L., Harrison, G., Elliott, J., Sardini, A., Higgins, C.F. Raguz, S. (2003) P-glycoprotein (MDR1) expression in leukaemic cells is regulated at two distinct steps, mRNA stabilisation and translational initiation. Journal of Biological Chemistry, 278, 10344 10352.
175. Yan, Q. Sadee, W. (2000) Human membrane transporter database: a web-accessible relational database for drug transport studies and pharmacogenomics. AAPS PharmSci, 2, E20.
176. Yang, J.M., Vassil, A.D. Hait, W.N. (2001) Activation of phospholipase C induces the expression of the multi-drug resistance (MDR1) gene through the Raf-MAPK pathway. Molecular Pharmacology, 60, 674 680.
177. Zhang, Z., Wu, J.Y., Hait, W.N. Yang, J.M. (2004) Regulation of the stability of P-gp by ubiquitination. Molecular Pharmacology, 66, 395 403.
178. Zmuidinavicius, D., Japertas, P., Petrauskas, A. Didziapetris, R. (2003) Progress in toxinformatics: the challenge of predicting acute toxicity. Current Topics in Medicinal Chemistry, 3, 1301 1314.